To Test or Not to Test? Ask Anvita Health.
Thursday, July 3rd, 2008 by Kelly BurkettMy Seattle Mariners may not be hitting any home runs (um, yeah — they’re dead last in the league), but respected Chilmark Research analyst John Moore did just with his recent analysis of our client Anvita Health. In “P4P, Change & Vested Interests,” Moore took a deep look at Anvita Health’s relationship with the Beth Israel Deaconess Physicians Organization (BIDPO), a 1,500-strong organization of doctors affiliated with the Beth Israel Deaconess Medical Center.
Anvita Health’s “blazingly fast” analysis engine (as described by Moore) works with BIDPO and Blue Cross Blue Shield of Massachusetts, serving as the glue between the two organizations to provide point-of-care clinical decision support and instantaneous pre-authorization approval for all high-tech, high-cost imaging tests. (As an aside, imaging is the single most expensive aspect of healthcare, and will cost an estimated $30 billion — that’s billion with a B — in 2008.)
The three-way partnership is a resounding success and one that could be emulated across the country to address an increasingly hot-button topic in healthcare — to test or not to test? (The New York Times recently looked at this very issue.) Where should the line between necessary imaging and overzealous employment exist? For the 1,500 physicians at BIDPO, Anvita Health helps them make the distinction.
